The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
HCV Genotype 4, 5, and 6: Distribution of Viral Subtypes and Sustained Virologic Response Rates in Clinical Trials of Approved Direct-acting Antiviral Regimens
1
Food and Drug Administration, Center for Drug Evaluation and Research, Office of Antimicrobial Products, Division of Antiviral Products, Silver Spring, Maryland.
Abstract
Multiple direct-acting antiviral (DAA)-based regimens are now available for all hepatitis C virus (HCV) genotypes (GTs). Because HCV GT 4, 5, and 6 are less common in the United States (US) and worldwide, relatively small numbers of participants with these GTs were evaluated in individual clinical trials. To provide a comprehensive description of subtype diversity and treatment outcomes in clinical trials for these less common GTs, we analyzed data from 744 participants with HCV GT4 (n=573), GT5 (n=81), or GT6 (n=90) across 18 clinical trials of DAA regimens. These data are from US New Drug Applications submitted between 2014 and 2017, and our analyses included only approved regimens. Excluding unresolved or mixed subtypes, the distribution of reported GT4 subtypes was 49% 4a, 31% 4d, and 16% for one of 14 other subtypes. The distribution of GT6 subtypes was 39% 6a, 27% 6e, 8% 6l, and 23% for one of 11 other subtypes. Across approved regimens, sustained virologic response rates 12 weeks post-treatment (SVR12) for GT 4, 5, and 6 ranged from 91%-100%, 93%-97%, and 96%-100%, respectively. SVR12 by GT4 subtype ranged from 96%-100% for 4a and 81%-100% for 4d. Virologic failures occurred in GT 4a, 4b, 4d, and 4r. For GT6, SVR12 was 100% for all subtypes except 6l, for which 1 of 7 participants experienced virologic failure. To our knowledge, this is the largest compilation of HCV GT 4, 5, or 6 clinical trial data. These analyses may be useful for clinicians treating HCV GT 4, 5, or 6.